New Releases from NCBI BookshelfAtezolizumab (NSCLC, adjuvant): Benefit assessment according to §35a SGB V (expiry of the decision): IQWiG Reports – Commission No. A24-102 [Internet].​Atezolizumab (NSCLC, adjuvant): Benefit assessment according to §35a SGB V (expiry of the decision): IQWiG Reports – Commission No. A24-102 [Internet].